GLP-1 & weight-loss clinical trials in Louisiana
11 GLP-1 or weight-loss trials are recruiting in Louisiana as of July 14, 2026, with sites in Baton Rouge, Lafayette, Lake Charles, New Iberia, Shreveport. Many studies reimburse time and travel — the amount is set by each study and confirmed when you contact the team.
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Phase 4 · ~200 participants · NCT06864026
Studied intervention: Tirzepatide
Louisiana site: Lake Charles
- A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Phase 1 · ~80 participants · NCT07184086
Studied intervention: CagriSema (Cagrilintide B + semaglutide I)
Louisiana site: Baton Rouge
- GLP-1R Actions on Muscle and the Skeleton
Phase 4 · ~50 participants · NCT07154719
Studied intervention: Tirzepatide
Louisiana site: Baton Rouge
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Phase 3 · ~125 participants · NCT06672549
Studied intervention: Orforglipron
Louisiana site: Lafayette
- Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Phase 3 · ~1200 participants · NCT07284979
Studied intervention: Semaglutide
Louisiana site: Shreveport
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Phase 3 · ~150 participants · NCT06672939
Studied intervention: Orforglipron
Louisiana site: Lafayette
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Phase 3 · ~290 participants · NCT06937099
Studied intervention: Tirzepatide
Louisiana sites: New Iberia, Shreveport
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Phase 3 · ~460 participants · NCT07253285
Studied intervention: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Louisiana site: Baton Rouge
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Phase 3 · ~586 participants · NCT07035093
Studied intervention: Retatrutide
Louisiana site: Lake Charles
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Phase 3 · ~350 participants · NCT06937086
Studied intervention: Tirzepatide
Louisiana sites: New Iberia, Shreveport
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Phase 2 · ~200 participants · NCT07446998
Studied intervention: Semaglutide (Wegovy) weekly injection
Louisiana site: Baton Rouge
What joining a GLP-1 trial in Louisiana actually involves
Every study above is registered on ClinicalTrials.gov, the US National Library of Medicine's public registry, and each link goes straight to that record — the one place the eligibility criteria, the schedule of visits and the contact details are kept current. A recruiting listing means the study is actively enrolling; it does not mean you are eligible until the study team screens you.
- Reimbursement is not the same as payment. Many studies cover time and travel, but the amount is set per study and confirmed by the team — treat any specific figure you see elsewhere as unverified until they tell you.
- You may receive a placebo. Most of these are randomized, so joining is not a guaranteed route to the active drug. That is worth weighing if your goal is treatment rather than contributing to the evidence.
- Trial participation is free to join and separate from a prescription. If your aim is to start a GLP-1 now, compare the cash-pay routes instead — trials are a different path with a different purpose.
Source: ClinicalTrials.gov (US National Library of Medicine), public-domain data, snapshot July 14, 2026. This is not medical advice or a recruitment service — confirm status, eligibility, and compensation on each linked ClinicalTrials.gov record and discuss any trial with your clinician.